AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA
The FDA has granted AstraZeneca's NDA218197 for Capivasertib an Approval Pending (AP) status.
Therapeutic Area
Therapeutic area intelligence for AKT Inhibitor with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.